Compare Becton Dickinson and Co (BDX) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Wendys Co — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Wendys Co trades at $7.54 (market cap $1.39B). The key difference: Becton Dickinson and Co is far larger — about 35.2× Wendys Co's market cap, and Wendys Co pays the higher dividend (3.84%). Which is the better fit depends on your goals.
| BDX | WEN | |
|---|---|---|
Market Cap | $48.93B | $1.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $10.68 |
52-Week Low | $138.62 | $6.17 |
Enterprise Value | $65.03B | $5.12B |
Dividend Yield | 2.34% | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Wendy's stock (WEN) trades at $7.69, up 4.06% in the last session, with a bullish technical signal from moving averages and a consensus price target of $9.33. Recent Q2 2026 EPS beat estimates at $0.18, but revenue trends show stagnation near $2.2B, with net income declining to $165M in 2025. The company faces headwinds from a dividend cut and lost market share to Burger King, as new leadership pursues a turnaround plan amid weak U.S. traffic.
The outlook is cautious; valuation ratios like P/E of 11.67 and P/S of 0.67 suggest undervaluation, but high debt and competitive pressures pose risks. Analyst sentiment is mixed with 62.75% hold ratings, reflecting uncertainty over the turnaround's success. Near-term performance hinges on execution of strategic initiatives to revive sales and margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
